Armed ImmunoCytokine Platform, AIC™

Our AIC™ Platform is prominently positioned in the...

more >>

ADCC Enhanced Antibody Platform, AEA™

Our AEA™ Platform is a biologically engineered Chi...

more >>

Armed Innate-effector Multispecific Platform, AIM™

Our AIM™ Platform focuses on designing multi-funct...

more >>
About SunHo
  • 9

    innovative and differentiated R&D pipelines, 6 of them are in the clinical stage
  • 117

  • 62.2%

    R&D members with master degree and above
more >>


SunHo is a biopharmaceutical company committed to the discovery, development and commercialization of first-in-class/best-in-class biologics that regulate immune microenvironment by directly modulating both the innate and adaptive immune systems. Leveraging our deep understanding of immunology, we have developed various types of immunotherapies including immunocytokines to treat cancers and autoimmune diseases.

Our commitment to innovation is evident and supported by our proprietary technology platforms, which include (i) AIC™ Platform, a scalable platform mainly concentrated on antibody-cytokine fusion protein development, (ii) ADCC Enhanced Antibody Platform (“AEA™ Platform”), a FUT8 knock-out cell line constructed to enhance the cytotoxicity of antibodies, and (iii) Armed Innate Effector Multi-specific Platform (“AIM™ Platform”), a platform that focuses on the development of innate immunity stimulator-based bispecific/multi-specific antibodies. Through our proprietary ...